Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP184543.RAQuzeXqwR1ETLyv1fEmao6VrqeBZFWHvyhQu9ayWZa4I130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP184543.RAQuzeXqwR1ETLyv1fEmao6VrqeBZFWHvyhQu9ayWZa4I130_assertion type Assertion NP184543.RAQuzeXqwR1ETLyv1fEmao6VrqeBZFWHvyhQu9ayWZa4I130_head.
- NP184543.RAQuzeXqwR1ETLyv1fEmao6VrqeBZFWHvyhQu9ayWZa4I130_assertion description "[A proportion of Alzheimer's disease (AD) patients treated for several months with cholinesterase (ChE) inhibitors have shown some favorable response on cognition, but the characteristics of the responders are still unclear.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP184543.RAQuzeXqwR1ETLyv1fEmao6VrqeBZFWHvyhQu9ayWZa4I130_provenance.
- NP184543.RAQuzeXqwR1ETLyv1fEmao6VrqeBZFWHvyhQu9ayWZa4I130_assertion evidence source_evidence_literature NP184543.RAQuzeXqwR1ETLyv1fEmao6VrqeBZFWHvyhQu9ayWZa4I130_provenance.
- NP184543.RAQuzeXqwR1ETLyv1fEmao6VrqeBZFWHvyhQu9ayWZa4I130_assertion SIO_000772 11125238 NP184543.RAQuzeXqwR1ETLyv1fEmao6VrqeBZFWHvyhQu9ayWZa4I130_provenance.
- NP184543.RAQuzeXqwR1ETLyv1fEmao6VrqeBZFWHvyhQu9ayWZa4I130_assertion wasDerivedFrom befree-20140225 NP184543.RAQuzeXqwR1ETLyv1fEmao6VrqeBZFWHvyhQu9ayWZa4I130_provenance.
- NP184543.RAQuzeXqwR1ETLyv1fEmao6VrqeBZFWHvyhQu9ayWZa4I130_assertion wasGeneratedBy ECO_0000203 NP184543.RAQuzeXqwR1ETLyv1fEmao6VrqeBZFWHvyhQu9ayWZa4I130_provenance.